Capsule summary. LTD4, the conversion product of LTC4, potently elicits bronchoconstriction, but blocks LTC4-induced platelet activation, pulmonary eosinophilia, and IL-33 induction through CysLT2R. Conversion to LTD4 may limit the severity of allergic inflammation potentiated by LTC4 production.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου